Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.46 |
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512721 | 1.00 | TNK2 (0.49) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL15167800 | 0.88 | GRM1 (0.49) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL74150 | 0.87 | TNK2 (0.49) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL1463273 | 0.87 | GRM1 (0.51) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL22820579 | 0.85 | BTK (0.51) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL26132375 | 0.83 | LIMK1 (0.37) | TNK2 | |
| SCHEMBL18009522 | 0.82 | GRM1 (0.53) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL15168000 | 0.81 | TNK2 (0.50) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL1585582 | 0.81 | TNK2 (0.55) | TNK2CYP11B2GRM1GRM5PDK4 | |
| SCHEMBL21060469 | 0.80 | GRM1 (0.55) | TNK2CYP11B2GRM1GRM5PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | TNK2 285/4885CYP11B2 2103/4885GRM1 4292/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | TNK2 285/4885CYP11B2 2103/4885GRM1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.